Immediate outcomes data could be known earlier without need to jeopardize the "90 days follow up" results.
The study could be partially unblinded to certain statisticians for the mortality data (one day will be enough, 15 minutes for calculations and the rest to digest the good or bad results before the pr news).
The clinicians following the neurobehavioral outcomes need not to be unblinded for their follow up examinations.
Patients themselves will not need to be unblinded.
This could have being pre-planned (was it?) or could be work out now. it is feasible.
If it was not planned it could be more expensive.
Xoma's interest to know earlier? shareholders? FDA ? Clinicians? patients?
Xoma could try to get some more money (floorless) before the final data is out base on the fame of the "(un)completed phase III".
Or could expend the actual floorless, and hope for the best when they are cashless.
Or could get initial data out, hope for the best and if good then to work for the money/partners with full force leverage, no more florless.
if bad.... to work with GNE takeover at $0.25 per share.
Even if partial data is costly the time saving ,the lack of need for another floorless, the leverage force, the share price and the possible partners will pay handsomely for the extra cost of partial blindness.
Technically is feasible. Does FDA have power over this?
Will FDA tolerate the data out? the Bluegreens of the world claiming freedom?
Let's FACE it, there is nothing if there is no impact on mortality.
Saving lives is the drug value.
Let's FACE it, either make it or $0.25 per share.
Edward 10,000 shares? please, say is not true.
I mean comedy, not tragedy when I say entertainment. |
